Naz Sobia, Sultana Nadra
Foundation University Medical College, Fauji Foundation Hospital, Rawalpindi.
J Pak Med Assoc. 2007 Mar;57(3):129-32.
To assess efficacy, safety and cost effectiveness of misoprostol (prostaglandin E1 analogue) for termination of pregnancy.
A descriptive study was conducted from March 2003 to December 2004, at Fauji Foundation Hospital Rawalpindi. A total of 200 patients, at 10-28 weeks of gestation, requiring termination of pregnancy were included. Each woman received first dose of 400 microg of misoprostol vaginally. Second dose of 400 microg of misoprostol was administered after 4 hours, according to the cervical dilatation, softening and uterine contractions. Oxytocin infusion was started after six hours of administration of first dose of Misoprostol, depending upon the uterine contractility. The process of abortion was monitored to assess the outcome measures.
Successful abortion was seen in 137 (68%) patients, with induction to delivery interval of 12.2 hours. In 40 (20%) patients surgical evacuation was performed. Out of 40 patients, 27 (13.5%) underwent surgical evacuation due to incomplete abortion and 13 (6.5%) for excessive per-vaginal bleeding. A total of 23 (12%) patients had failure of method for induction of abortion and needed either repeat dose of misoprostol after 24 hours or other methods of induction (besides misoprostol). Side effects included nausea, vomiting, diarrhoea and fever. Mean hospital stay for induction of abortion was 31 hours.
Misoprostol is safe, efficacious and a cost effective drug for induction of the first and the second trimester abortions.
评估米索前列醇（前列腺素E1类似物）用于终止妊娠的疗效、安全性及成本效益。
2003年3月至2004年12月在拉瓦尔品第的法吉基金会医院进行了一项描述性研究。纳入了总共200例妊娠10 - 28周需要终止妊娠的患者。每位女性经阴道给予首剂400微克米索前列醇。4小时后根据宫颈扩张、软化及子宫收缩情况给予第二剂400微克米索前列醇。首剂米索前列醇给药6小时后，根据子宫收缩情况开始静脉滴注缩宫素。监测流产过程以评估结局指标。
137例（68%）患者流产成功，引产至分娩间隔时间为12.2小时。40例（20%）患者进行了手术清宫。在这40例患者中，27例（13.5%）因流产不全接受了手术清宫，13例（6.5%）因阴道出血过多接受了手术清宫。共有23例（12%）患者引产方法失败，需要在24小时后重复给予米索前列醇剂量或采用其他引产方法（除米索前列醇外）。副作用包括恶心、呕吐、腹泻和发热。引产平均住院时间为31小时。
米索前列醇是一种安全、有效且具有成本效益的用于诱导早期及中期妊娠流产的药物。
